alpha particle

(redirected from Alpha emitter)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

al·pha par·ti·cle (α),

a particle consisting of two neutrons and two protons, with a positive charge (2e+); emitted energetically from the nuclei of unstable isotopes of high atomic number (elements of mass number from 82 up); identical to the helium nucleus.
Synonym(s): alpha ray

alpha particle

a particle emitted from an atom during one kind of radioactive decay. It consists of two protons and two neutrons, the equivalent of a helium nucleus. Ordinarily, alpha particles are a weak form of radiation with a short range and are not considered hazardous unless inhaled or ingested.

alpha particle

A radioactive decay product, 4He nucleus, composed of two protons and two neutrons (the same as the nucleus of a helium-4 atom) with marked ionising capacity (3–9 million electron-volts) but a short range (3–9 cm in air, 25–40 µm in water/soft tissue), derived from alpha decay, which are created by the decay of a radioactive material or from nuclear bombardment. APs arising from radon, uranium and plutonium “daughters” are implicated in inhalation-induced neoplasia of the respiratory tract.

While alpha particles are highly tissue-destructive, they travel only short distances and are blocked by a thick piece of paper or skin; an AP is essentially a helium atom nucleus and generally carries more energy than gamma or beta radiation, depositing that energy very quickly while passing through tissue. Alpha particles cannot penetrate the outer, dead layer of skin; they therefore do not cause damage to living tissue when outside the body. When inhaled or ingested, however, APs are especially damaging because they transfer relatively large amounts of ionising energy to living cells.

alpha particle

a type of subatomic particle found in the atomic nucleus.

al·pha par·ti·cle

(alfă pahrti-kĕl)
A particle consisting of two neutrons and two protons, with a positive charge; emitted energetically from the nuclei of unstable isotopes of mass number 82 and up.
Synonym(s): alpha ray.
References in periodicals archive ?
The global market for alpha emitters can be segmented on the basis of radionuclide used (Terbium, Astatine, Bismuth, Actinium, Radium, Lead, Bismuth (Bi-213) and Others), type of medical application (Endocrine tumors, Lymphoma, Bone metastasis, Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid and Others), on the basis of Geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa).
The therapeutic radiopharmaceuticals market is further segmented into beta emitters, alpha emitters, and brachytherapy.
Furthermore, multiaberrant cells, characteristic for incorporated alpha emitters, were identified well beyond 100 km from Chernobyl, whereas plutonium particles were found as far away as Norway, contradicting "negligible exposure levels" beyond 100 km [International Physicians for the Prevention of Nuclear War (IPPNW) 2006; Schmitz-Feuerhake 2006; Schmitz-Feuerhake et al.
com/research/5bvmb7/nuclear) has announced the addition of the "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020" report to their offering.
Experiments for remote location of Alpha emitters by UV technology are performed together with STUK.
We do not dispute Nussbaum's argument that additional doses may have been received from alpha emitters incorporated internally and that these might have been more than is acknowledged by UNSCEAR and the World Health Organization (WHO).
According to a new market research report The report " Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90), by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020 " , published by MarketsandMarkets, this report studies the global Nuclear Medicine/Radiopharmaceuticals Market for the forecast period of 2015 to 2020.
This extension consists of a concrete building nuclear processes and for the storage of radioactive nuclear materials: alpha emitters, beta emitters and gamma emitters (mainly tritium).
Alpha emitters which use bismuth-213 and astatine-211 labeled monoclonal antibodies in patients with leukemia and brain tumor and radium- 223 are being evaluated in breast and prostate cancer patients with bone metastases.